Characteristics of study population
| AT, anaerobic threshold; GTN, glyceryl trinitrate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NYHA, New York Heart Association; pVO2, peak oxygen consumption; VCO2, carbon dioxide output; VE, ventilatory equivalent; VO2, maximum oxygen uptake. | |
| *As recorded at the last cardiology outpatient appointment. | |
| Cause of disease (% ischaemic/% non-ischaemic) | 85%/15% |
| NYHA class*, n (%) | |
| I | 8 (17.8) |
| II | 22 (48.9) |
| III | 13 (28.9) |
| IV | 2 (4.4) |
| Drugs (% of patients prescribed drug) | |
| Digoxin | 22.5 |
| Diuretics | 67.5 |
| ACE inhibitors | 65.1 |
| Angiotensin II antagonists | 20 |
| Warfarin | 25 |
| Antiarrythimics | 15 |
| β-Blockers | 62.5 |
| Spironolactone | 40 |
| Aspirin | 50 |
| Clopidogrel | 2.5 |
| Statin | 72.5 |
| Calcium channel blockers | 12.5 |
| Isosorbide mononitrate | 20 |
| GTN spray | 0 |
| Blood test results (mean (SD)) | |
| LDL cholesterol | 2.34 (1.2) |
| Creatinine | 129.1 (40.1) |
| Cholesterol | 4.3 (1.5) |
| Cholesterol/HDL ratio | 3.4 1.0 |
| Sodium | 138.1 (3.5) |
| Potassium | 4 (0.6) |
| Cardiopulmonary testing | |
| pVO2 | 14.8 (7.3) |
| VE/VCO2 | 44 (16.2) |
| VO2 at AT | 8.8 (3.6) |